Literature DB >> 24138595

Immunophenotypic and molecular features of 'cuplike' acute myeloid leukemias.

Paola Carluccio1, Anna Mestice, Domenico Pastore, Mario Delia, Alessandra Ricco, Antonella Russo-Rossi, Paola Casieri, Arcangelo Liso, Maria Paola Martelli, Francesco Albano, Giorgina Specchia.   

Abstract

Nuclear invaginations, also referred to as fishmouth or cuplike nuclei, have long been identified in microgranular APL, myelomonocytic and monocytic AMLs. More recently, this typical morphological feature has been associated with NPM1 and FLT3 mutations, as well as with the lack of CD34 and HLA-DR expression. In this study, we retrospectively analyzed the morphologic, immunophenotypic, cytogenetic, and molecular features of 68 patients with AML. A cuplike nuclear invagination was detected in more than 10% of blast cells in 15 (22%) cases. Our data show that a cuplike morphology is associated with FLT3-ITD positivity, as well as with the loss of CD34 and HLA-DR expression. The results were not significantly modified when a higher cutoff of cuplike cells was used. Our results are not sufficient to suggest that cuplike AML could represent a distinct subtype, but further investigations could yield a better characterization of this feature in patients with AML.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  FLT3; NPM1; acute myeloid leukemia; cuplike morphology

Mesh:

Substances:

Year:  2014        PMID: 24138595     DOI: 10.1111/ejh.12217

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  1 in total

1.  Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine.

Authors:  Jie Sun; Shangyong Ning; Ru Feng; Jiangtao Li; Ting Wang; Baoli Xing; Xiaoquan Zhu; Yanyang Zhao; Lei Pei; Hui Liu
Journal:  Anticancer Drugs       Date:  2022-01-01       Impact factor: 2.248

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.